<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342364</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2020-02</org_study_id>
    <nct_id>NCT04342364</nct_id>
  </id_info>
  <brief_title>Oocyte Survival After Vitrification With Slush Nitrogen Compared With Liquid Nitrogen</brief_title>
  <official_title>Oocyte Survival After Vitrification With Slush Nitrogen Compared With Liquid Nitrogen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of slush nitrogen results in higher
      post-thaw survival rates for oocytes compared to conventionally used liquid nitrogen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, controlled trial which seeks to characterize oocyte survival rate
      following vitrification and subsequent warming with both slush nitrogen and liquid nitrogen.
      After warming, fertilization and embryology outcomes will be assessed.

      Oocyte donors and a single donor sperm source will be utilized. Following enrollment, oocyte
      donors will undergo ovarian stimulation and oocyte retrieval. The mature (MII) oocytes
      obtained for each patient will then be assigned a number and randomized via block
      randomization to one of two treatment groups (liquid nitogen or slush nitrogen). Through
      block randomization, this will create a paired population of oocytes so that half of each
      patient's oocytes will undergo cryopreservation with liquid nitrogen and half will undergo
      cryopreservation with slush nitrogen. Timing of hyaluronidase stripping and vitrification
      will be consistent with current institutional clinical practice for oocytes.

      Following cryopreservation, oocytes will be warmed and intracytoplasmic sperm injection will
      be performed and subsequent embryology outcomes tracked.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial in a paired design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>embryologist assessing oocyte survival (primary outcome) is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>oocyte survival rate</measure>
    <time_frame>within 5 minutes post warming</time_frame>
    <description>number of viable oocytes post warming</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>18 hours post injection</time_frame>
    <description>number of zygotes post intracytoplasmic sperm injection procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blastulation rate</measure>
    <time_frame>4-6 days after fertilization</time_frame>
    <description>number of zygotes reaching the blastocyst stage of embryo development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>euploid rate</measure>
    <time_frame>1 week after trophectoderm biopsy</time_frame>
    <description>number of chromosomally normal embryos</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Slush nitrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oocytes are randomized to undergo vitrification utilizing slush nitrogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid Nitrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitrification via slush nitrogen</intervention_name>
    <description>oocytes will be vitrified using slush nitrogen</description>
    <arm_group_label>Slush nitrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitrification via liquid nitrogen</intervention_name>
    <description>oocytes will be vitrified using liquid nitrogen which is currently routine practice</description>
    <arm_group_label>Liquid Nitrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria for oocyte donors:

          1. Age 30 years or younger who meet institutional criteria to be an oocyte donor.

          2. Patients who agree to donate oocytes for research purposes and agree to the study
             protocol.

          3. The subgroup of oocyte donors age 35-38 will not be part of the primary analysis, and
             therefore will not be required to meet the age criteria listed above. The older group
             of donors will be chosen as the clinical discretion of the study investigators. No
             specific ovarian reserve cutoffs will be required, although factors related to ovarian
             reserve will be taken into consideration.

        Major Exclusion Criteria for oocyte donors:

          1. Under 18 years old

          2. All patients who do not voluntarily give their written consent for participation.

          3. Patients who do not meet standard institutional criteria for oocyte donation.

          4. A diagnosis of polycystic ovarian syndrome (PCOS).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine V Whitehead, BSN, RN</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Zuckerman, BS</last_name>
    <phone>973-656-2841</phone>
    <email>clinicalresearchteam@ivirma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine V Whitehead, BSN,RN</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Zuckerman, BS</last_name>
      <phone>973-656-2841</phone>
      <email>clinicalresearchteam@ivirma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard T Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

